These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11150155)

  • 1. [Prostatic hormone-resistant cancer: present-day drug prophylaxis and treatment].
    Sivkov AV; Alfimov AE; Imamov OE
    Urologiia; 1999; (5):33-9. PubMed ID: 11150155
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 3. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach.
    Gardiner RA; Sweeney C; Tilley WD
    Eur Urol; 2009 Aug; 56(2):245-6. PubMed ID: 19409691
    [No Abstract]   [Full Text] [Related]  

  • 4. Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction?
    Berry WR
    Nat Clin Pract Oncol; 2005 Apr; 2(4):180-1. PubMed ID: 16264926
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
    Syed S
    Cancer; 2003 Nov; 98(10):2088-90. PubMed ID: 14601076
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro antiproliferation in prostate cancer cell lines with cytostatics and combinations with resistance modifiers.
    Pintér O; Mucsi I; Molnár J
    In Vivo; 2005; 19(1):253-9. PubMed ID: 15796183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study.
    Stathopoulos GP; Koutantos J; Vaslamatzis MM; Athanasiadis A; Papadopoulos G; Labrodimou G; Stathopoulos J; Rigatos S
    Oncol Rep; 2009 Aug; 22(2):345-8. PubMed ID: 19578775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
    Lin AM; Ryan CJ; Small EJ
    Crit Rev Oncol Hematol; 2007 Mar; 61(3):243-54. PubMed ID: 17161610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
    Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E
    Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early diagnosis and early treatment of prostatic tumors].
    Gaca A
    Hippokrates; 1967 Dec; 38(24):966-70. PubMed ID: 4180645
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current role of chemotherapy in the treatment of hormone-resistant prostatic cancer].
    Soulie M; Beuzeboc P; Irani J; Davin JL
    Prog Urol; 2006 Jun; 16(3):394-5. PubMed ID: 16821362
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hormonal treatment of advanced prostate cancer].
    Faris G; Stein A; Lurie A
    Harefuah; 1993 Jan; 124(1):35-40. PubMed ID: 8436310
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of hormonal refractory metastatic prostate cancer].
    Sengeløv L; Klarskov OP; Karlsson S
    Ugeskr Laeger; 2007 May; 169(20):1905-7. PubMed ID: 17553368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of chemotherapy in the treatment of prostatic carcinoma.
    Tonato M; Bracarda S
    Rays; 1993; 18(1):87-93. PubMed ID: 8356244
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer].
    Breton X; Lechevallier E; Coulange C
    Prog Urol; 2005 Jun; 15(3):398-404. PubMed ID: 16097142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
    Culine S
    Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025
    [No Abstract]   [Full Text] [Related]  

  • 18. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hormonal therapy in the treatment of prostatic carcinoma.
    Di Silverio F; D'eramo G; Caponera M; Flammia GP; Izzi R; Sciarra A; Macrì D; Buscarini M
    Rays; 1993; 18(1):94-114. PubMed ID: 8356245
    [No Abstract]   [Full Text] [Related]  

  • 20. [Re: "Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404].
    Berdah JF
    Prog Urol; 2005 Dec; 15(6):1160. PubMed ID: 16429675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.